Predictive Factors of Decompensation and Death in 670 Patients with Hepatitis C Treated with Direct-Acting Antivirals
1. Abstract Sustained virological response 12 weeks after treatment (SVR12) with direct-acting antivirals (DAAs) is excellent in patients with hepatitis C but little has been published regarding decompensation and/or death during therapy. 1.1. Objectives: Objectives of this prospective, observational, multicenter study were to describe SVR12 in real life patients with advanced fibrosis/cirrhosis treated with DAAs …